ADAP Adaptimmune Therapeutics PLC

  1. Stocks
  2. Healthcare
  3. NASDAQ: ADAP

Price (delayed)

$1.39

Market cap

$355.94M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.66

Enterprise value

$236.11M

Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform ...

Highlights
Adaptimmune Therapeutics's EPS has decreased by 22% from the previous quarter but it has increased by 8% YoY
The company's quick ratio rose by 13% QoQ but it fell by 12% YoY
The company's revenue has shrunk by 74% YoY and by 70% QoQ
Adaptimmune Therapeutics's gross profit has shrunk by 74% YoY and by 70% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.adaptimmune.com
Peers: CRL ENZ NVAX EXEL

Key stats

What are the main financial stats of ADAP
Market
Shares outstanding
256.07M
Market cap
$355.94M
Enterprise value
$236.11M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
14.1
Price to sales (P/S)
18.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.86
Earnings
Revenue
$18.36M
EBIT
-$162.17M
EBITDA
-$151.35M
Free cash flow
-$137.98M
Per share
EPS
-$0.66
Free cash flow per share
-$0.57
Book value per share
$0.1
Revenue per share
$0.08
TBVPS
$1.06
Balance sheet
Total assets
$258.01M
Total liabilities
$233.64M
Debt
$23.69M
Equity
$24.38M
Working capital
$120.49M
Liquidity
Debt to equity
0.97
Current ratio
2.81
Quick ratio
2.33
Net debt/EBITDA
0.79
Margins
EBITDA margin
-824.4%
Gross margin
100%
Net margin
-890.1%
Operating margin
-1,038.6%
Efficiency
Return on assets
-55.4%
Return on equity
-234.6%
Return on invested capital
-123.5%
Return on capital employed
-84.6%
Return on sales
-883.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ADAP stock price

How has the Adaptimmune Therapeutics stock price performed over time
Intraday
6.92%
1 week
18.8%
1 month
67.47%
1 year
49.46%
YTD
75.28%
QTD
43.3%

Financial performance

How have Adaptimmune Therapeutics's revenue and profit performed over time
Revenue
$18.36M
Gross profit
$18.36M
Operating income
-$190.66M
Net income
-$163.41M
Gross margin
100%
Net margin
-890.1%
The company's revenue has shrunk by 74% YoY and by 70% QoQ
Adaptimmune Therapeutics's gross profit has shrunk by 74% YoY and by 70% QoQ
ADAP's operating income has plunged by 70% YoY and by 36% from the previous quarter
Adaptimmune Therapeutics's net income has decreased by 44% QoQ and by 43% YoY

Growth

What is Adaptimmune Therapeutics's growth rate over time

Valuation

What is Adaptimmune Therapeutics stock price valuation
P/E
N/A
P/B
14.1
P/S
18.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.86
Adaptimmune Therapeutics's EPS has decreased by 22% from the previous quarter but it has increased by 8% YoY
ADAP's price to book (P/B) is 120% higher than its last 4 quarters average of 6.0
Adaptimmune Therapeutics's equity has plunged by 71% YoY and by 38% from the previous quarter
The P/S is 142% above the last 4 quarters average of 7.1 but 85% below the 5-year quarterly average of 118.0
The company's revenue has shrunk by 74% YoY and by 70% QoQ

Efficiency

How efficient is Adaptimmune Therapeutics business performance
The return on equity has dropped by 116% year-on-year and by 74% since the previous quarter
The company's return on invested capital has shrunk by 107% YoY and by 59% QoQ
Adaptimmune Therapeutics's return on assets has shrunk by 62% YoY and by 47% QoQ

Dividends

What is ADAP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADAP.

Financial health

How did Adaptimmune Therapeutics financials performed over time
ADAP's total assets is 10% greater than its total liabilities
ADAP's current ratio is down by 16% YoY
ADAP's total liabilities is up by 14% YoY but it is down by 3.9% QoQ
The debt is 2.8% smaller than the equity
Adaptimmune Therapeutics's equity has plunged by 71% YoY and by 38% from the previous quarter
ADAP's debt to equity has surged by 52% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.